Figure 2 | Scientific Reports

Figure 2

From: Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

Figure 2

Individual details of patient factors with genomic alterations including SNVs and CNAs in RTK-RAS and cell cycle pathway (A). The cell cycle pathway was the only pathway that showed statistically significant (q-value 6 × 10–4) results among 10 oncogenic signaling pathways (B). The frequency of cell cycle genomic alterations was lowest, 27% in LTRs, 58% in IRs and enriched (100%) in de novo resistance.

Back to article page